About this episode
Neha J. Pagidipati, MD, FACC, JACC Associate Editor, and Richard Pratley, MD, discuss insights from the FLOW trial – revealing that semaglutide reduced heart failure events and cardiovascular death by approximately 27%, both in patients with and without prior heart failure.
Get every episode summarized
Each time JACC This Week publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from JACC This Week
March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this W...
JACC This Week
Mar 10, 202618:37failed
March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inh...
JACC This Week
Mar 3, 202618:10pending
February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC T...
JACC This Week
Feb 24, 202613:39pending
February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Red...
JACC This Week
Feb 17, 202621:53pending